Harmony Biosciences is a private biopharmaceutical company in Pennsylvania that focuses on developing and commercializes novel treatment options. Founded in 2017 in Plymouth Meeting, Pennsylvania, United States by Bob Repella, Harmony Biosciences focuses on the central nervous system, including disorders of sleep and wakefulness. The company is currently working to advance the understanding of narcolepsy and provide information and resources to people who live with, and healthcare professionals who treat, this chronic, debilitating neurological disorder. The company's biopharmaceuticals focus on selective histamine 3 (H3) receptor antagonists for patients who are struggling with narcolepsy, enabling patients to recover quickly from central nervous system disorders.
The company’s product, WAKIX (pitolisant hydrochloride tablet, film coated), is a histamine-3 (H3) receptor antagonist/inverse agonist indicated for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy.
Chief Business Officer
President, Chief Executive Officer & Member of the Board of Directors
Susan L Drexler
Chief Financial Officer